← Eichor
Condition: Lymphoma Receiving Car T Therapy Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Lymphoma Receiving Car T Therapy

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy
Phase 2 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT05757219Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies W
Phase N/A · 3 location(s) · National Cancer Institute (NCI) · NCT05237986Fecal Microbiota Transplantation in Patients Undergoing Chimeric Antigen Receptor T-cell Therapy and Allogeneic Stem Cel
NA · 1 location(s) · University Health Network, Toronto · NCT07509450Study of CTO1681 for the Prevention and Treatment of CRS in DLBCL Patients Receiving CAR T-Cell Therapy
Phase 1/Phase 2 · 6 location(s) · CytoAgents, Inc. · NCT05905328Looking at Cognitive and Brain Changes in People With Lymphoma Receiving CAR-T Therapy
Phase N/A · 1 location(s) · Memorial Sloan Kettering Cancer Center · NCT04107285Long-term Follow-up Study of Patients Receiving CAR-T Cells
Phase N/A · 1 location(s) · Medical College of Wisconsin · NCT03375619A Study of Voice as a Way to Monitor for Side Effects in People Receiving CAR T-Cell Therapy
Phase N/A · 8 location(s) · Memorial Sloan Kettering Cancer Center · NCT07249528Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
Phase N/A · 5 location(s) · Miltenyi Biomedicine GmbH · NCT06116110A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies
Phase 1/Phase 2 · 7 location(s) · Cancer Research UK · NCT06045910PET Imaging Study of 64Cu-GRIP B for Patients Receiving CD19-directed CAR-T Therapy
Phase 1 · 1 location(s) · Michael Randall · NCT06522932Optimizing lymphoDepletion to Improve Outcomes In Patients Receiving Cell Therapy With Yescarta
Phase 1 · 1 location(s) · University Health Network, Toronto · NCT05950802Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malig
Phase 1/Phase 2 · 13 location(s) · AvenCell Therapeutics, Inc. · NCT07284433
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.